pillbase.ru

Simulect

Active substance: basiliximab

basiliximab

Centralised EU authorisationActive

Marketing holder: Novartis Europharm Limited

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
RU 3
  • Симулект®
    лиофилизат для приготовления раствора для внутривенного введения, 20 мг, 20 мг (original in Russian, GRLS)
    ЛП-№(011247)-(РГ-RU)
    Новартис Фарма АГ
  • Симулект®
    лиофилизат для приготовления раствора для внутривенного введения, 20 мг, 20 мг (original in Russian, GRLS)
    П N011528/01
    Новартис Фарма АГ
  • Симулект
    лиофилизат для приготовления раствора для внутривенного введения, 10 мг, (original in Russian, GRLS)
    ЛС-001894
    Новартис Фарма АГ
US 3
  • Simulect
    INJECTION, POWDER, FOR SOLUTION · BASILIXIMAB 20 mg/5mL
    0078-0331
    Novartis Pharmaceuticals Corporation
  • Simulect
    INJECTION, POWDER, FOR SOLUTION · BASILIXIMAB 10 mg/2.5mL
    0078-0393
    Novartis Pharmaceuticals Corporation
  • basiliximab
    INJECTION, POWDER, FOR SOLUTION · BASILIXIMAB 10 mg/2.5mL
    17088-0370
    Novartis Pharma Stein AG
Import and control

Control by country

  • Russiaprescription only

    Source: GRLS (Russian state register) · record 01a120c3-c00a-7c73-9bec-57ebaddb184c,01a120c5-4c73-743c-9ad8-5b66f6bc919f,01a120c6-7613-78e1-bf9d-ce294e7ea4f7;count=3 · valid from 2026-10-09 · verified 2026-10-09

  • United Statesprescription only

    Source: openFDA NDC · record 01a12093-3c1f-71a0-b4e8-80f45b6c0e2d,01a12093-3f11-72f4-b8d2-664f8ff52f12,01a12097-e6f6-7b5b-ad79-35bacbc65ea4;count=3 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/000207
Registration status
Active
ATC code
L04AC02
Sources
  • product · EMA · EMEA/H/C/000207 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/000207 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/000207 · Verified 2026-10-09